Gemtuzumab ozogamicin (Mylotarg) for the treatment of acute myeloid leukemia - Ongoing trials

Onkologie

Volumn 30, Issue 12, 2007, Pages 657-662

  Gleissner, Beate ^a   Schlenk, Richard ^b   Bornhäuser, Martin ^c   Berdel, Wolfgang E ^d  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Acute myeloid leukemia; Gemtuzumab ozogamicin

Indexed keywords

AMSACRINE; ANTHRACYCLINE DERIVATIVE; CYCLOSPORIN; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; INTERLEUKIN 11; MITOXANTRONE; RETINOIC ACID; TIOGUANINE; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CHILL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEVER; GERIATRIC PATIENT; HEART DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; INFECTION; LIVER TOXICITY; LUNG DISEASE; MAINTENANCE THERAPY; METABOLIC DISORDER; MUCOSA INFLAMMATION; PNEUMONIA; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS; TRANSAMINITIS; TREATMENT RESPONSE;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; GERMANY; HUMANS; LEUKEMIA, MYELOID, ACUTE; PHYSICIAN'S PRACTICE PATTERNS; TREATMENT OUTCOME;

EID: 37049014093     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000109956     Document Type: Review

References (35)

1. Dillman RO, Davis RB, Green MR, Weiss RB, Gottlieb AJ, Caplan S, Kopel S, Preisler H, McIntyre OR, Schiffer C: A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 1991;78:2520-2526.
2. Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG, Burnett AK: Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML 10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 1997;89:2311-2318.
3. Buchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, Schnittger S, Kern W, Tchinda J, Reichle A, Lengfelder E, Staib P, Ludwig WD, Aul C, Eimermacher H, Balleisen L, Sauerland MC, Heinecke A, Wormann B, Hiddemann W: Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006;24:2480-2489.
4. Craddock C, Tauro S, Moss P, Grimwade D: Biology and management of relapsed acute myeloid leukaemia. Br J Haematol 2005;129:18-34.
5. Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W: Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 2004;50:197-222.
6. Ferrara F, Palmieri S, Mele G: Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. Haematologica 2004;89:998-1008.
7. Jackson G, Taylor P, Smith GM, Marcus R, Smith A, Chu P, Littlewood TJ, Duncombe A, Hutchinson M, Mehta AB, Johnson SA, Carey P, MacKie MJ, Ganly PS, Turner GE, Deane M, Schey S, Brookes J, Tollerfield SM, Wilson MP: A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol 2001;112:127-137.
8. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ, Frassoni F, Boiron JM, Yin JL, Finke J, Shouten H, Blaise D, Falda M, Fauser AA, Esteve J, Polge E, Slavin S, Niederwieser D, Nagler A, Rocha V: Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 2005;19:2304-2312.
9. Bacigalupo A, Sormani MP, Lamparelli T, Gualandi F, Occhini D, Bregante S, Raiola AM, di Grazia C, Dominietto A, Tedone E, Piaggio G, Podesta M, Bruno B, Oneto R, Lombardi A, Frassoni F, Rolla D, Rollandi G, Viscoli C, Ferro C, Garbarino L, Van Lint MT: Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Haematologica 2004;89:1238-1247.
10. Forman SJ, Blume KG, Thomas ED (eds): Hematopoietic Cell Transplantation. Boston, Blackwell Science, 2006, pp 823-834.
11. Frankel AE, Sievers EL, Scheinberg DA: Cell surface receptor-targeted therapy of acute myeloid leukemia: a review. Cancer Biother Radiopharm 2000;15:459-476.
12. Bernstein ID, Singer JW, Smith FO, Andrews RG, Flowers DA, Petersens J, Steinmann L, Najfeld V, Savage D, Fruchtman S: Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia. Blood 1992;79:1811-1816.
13. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF: A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 1984;8:521-534.
14. Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K, Feirt N, Finn RD, Clarkson BD, Gee TS: A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 1991;9:478-490.
15. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001;19:3244-3254.
16. Larson RA, Sievers EL, Stadtmauer EA, Lowenberg B, Estey EH, Dombret H, Theobald M, Voliotis D, Bennett JM, Richie M, Leopold LH, Berger MS, Sherman ML, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR: Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005;104:1442-1452.
17. Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ: Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 2003;51:87-90.
18. Chevallier P, Roland V, Mahe B, Juge-Morineau N, Dubruille V, Guillaume T, Vigouroux S, Moreau P, Milpied N, Garand R, vet-Loiseau H, Harousseau JL: Administration of Mylotarg 4 days after beginning of a chemotherapy including intermediatedose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 2005;29:1003-1007.
19. Cortes J, Tsimberidou AM, Alvarez R, Thomas D, Beran M, Kantarjian H, Estey E, Giles FJ: Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol 2002;50:497-500.
20. Fianchi L, Leoni F, Storti S, Rutella S, Gianfaldoni G, Voso MT, Bosi S, Pagano L, Leone G: Gemtuzumab-ozogamicin, citosine arabinoside, G-CSF combination in the treatment of elderly patients with poor prognosis acute myeloid leukemia. A multicentric study. Blood 2005;106:230B.
21. Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Gaitani S, Visani G, Baccarani M: First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leuk Res 2004;28:987-990.
22. Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S, Albitar M, Kantarjian H, Estey E, Giles FJ: Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 2003;27:893-897.
23. Schlenk RF, Doehner K, Kerz M, Hartman R, del Valle F, Glasmacher A, Pralle H, Goetze K, Koller E, Gastl G, Mergenthaler HG, Salwender H, Kirchen H, Haase D, Kremers S, Nerl C, Heobald M, Matzdorff AC, Ganser A, Doehner H for the German-Austrian AML Study Group AMLSG: All-trans retinoic acid and gemtuzumab ozogamicin as adjunct to salvage therapy in primary refractory acute myeloid leukemia: results of consecutive phase II studies of the AMLSG. Blood 2006;106:526a.
24. Burnett AK, Kell WJ, Goldstone AH, Milligan DW, Hunter A, Prentice AG, Russellm BG, Gibson B, Willemze R, Hills RK: The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity. Preliminary analysis of 1115 patients in the MTC AML15 trial. Blood 2006;106:8a.
25. Bornhauser M, Illmer T, Platzbecker U, Ordemann R, Schetelig J, Schaich M, Kiani A, Schuler U, Ehninger G: Gemtuzumab ozogamicin (Mylotarg®) followed by dose-reduced total-body irradiation and fludarabine as conditioning for allogeneic stem cell transplantation in patients with relapsed/refractory CD33+ acute myeloid leukaemia. Bone Marrow Transplant 2006;37:S121.
26. Amadori S, Suciu S, Stasi R, Willemze R, Mandelli F, Selleslag D, Denzlinger C, Muus P, Stauder R, Berneman Z, Pruijt J, Nobile F, Cassibba V, Marie JP, Beeldens F, Baila L, Vignetti M, de Witte T: Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. Leukemia 2005;19:1768-1773.
27. Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H, Giles FJ: Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 2003;27:887-891.
28. Kell WJ, Burnett AK, Chopra R, Yin JA, Clark RE, Rohatiner A, Culligan D, Hunter A, Prentice AG, Milligan DW: A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003;102:4277-4283.
29. Nabhan C, Rundhaugen L, Jatoi M, Riley MB, Boehlke L, Peterson LC, Tallman MS: Gemtuzumab ozogamicin (Mylotarg™) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease. Ann Oncol 2004;15:1231-1236.
30. Nabhan C, Rundhaugen LM, Riley MB, Rademaker A, Boehlke L, Jatoi M, Tallman MS: Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Leuk Res 2005;29:53-57.
31. Roboz GJ, Ritchie EK, Schuster MW, Shore T, Curcio TJ, Allen-Bard S, Provenzano JL, Feldman EJ: Gemtuzumab ozogamicin is an acceptable alternative to anthracyclines in combination with standard dose infusional cytarabine as induction therapy for elderly patients with acute myeloid leukemia (AML). Blood 2006;106:528a.
32. Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, Thomas DA, Ferrajoli A, Keating MJ, O'Brien S, Kantarjian HM, Giles FJ: Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as postremission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 2003;52:449-452.
33. De Angelo DJ, Stone RM, Durrant S, Liu D, Baccarani M, Schiffer CA, Amrein P, Sherman ML, Mylotarg Study Group: Gemtuzumab ozogamicin (Mylotarg) in combination induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: two age-specific phase 2 trials. Blood 2003;102:341a.
34. de Lima M, Giralt S, Caldera Z, McCormick G, Qazilbash M, Anderlini P, Shpall EJ, Hosing C, Donato M, Kornblau S, Khouri I, Martin T, Couriel D, Champlin R: Results of a phase I/II study of gemtuzumab ozogamicin added to fludarabine (F); melphalan (M) and allogeneic hematopoietic stem cell transplantation (HSCT) for relapsed myeloid leukemias. Blood 2006;106:248a.
35. Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M, Pierce SA, Thomas DA, Kantarjian HM: Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002;99:4343-4349.